Previous Close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.50 |
Expire Date | 2025-01-17 |
Day's Range | 0.0500 - 0.0500 |
Contract Range | N/A |
Volume | |
Open Interest | 8.24k |
Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to meet the evolving needs of the animal agriculture industry. By utilizing Ginkgo Enzyme Services, NOVUS will work with Ginkgo to build more efficient enzymes that can be produced cost-effectively.
Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient. Ginkgo Datapoints is specialized in generating large, high-quality biological datasets with a fast turnaround time and at a competitive price per datapoint with a streamlined deal structure. Ginkgo Datapoints will launch with severa
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced two new offerings that will make it easier for pharmaceutical and biotech companies to develop new medicines, building on the partnership announced with Google Cloud last year. The first launch is one of the first-of-its-kind in the industry – a protein large language model (LLM) built in collaboration with Google Cloud Consulting that will give individual rese